Use of histamine metabolites as markers for the treatment of ibs with h1-r antagonists

The invention relates to methods for determining whether treatment with an H1- receptor antagonist is likely to cure a visceral sensitivity disorder in a irritable bowel syndrome (IBS) patient or a functional dyspepsia patient comprising determining whether a body sample of said patient has increased levels of a histamine metabolite relative to levels in a normal tissue sample of a healthy individual, wherein an increase of a histamine metabolite is indicative for the effectivity of a treatment to be performed with said H1-receptor antagonist of said visceral sensitivity disorder.

Octrooi-publicatienummer: WO2017102640

Jaar aanvraag: 2016

Jaar toekenning: 2018

Jaar van publicatie: 2017

Status: Aangevraagd

Technologiedomeinen: Analyse van biologische materialen

Gevalideerd voor IOF-sleutel: Ja

Toegewezen aan: Associatie KULeuven